Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, ...

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers ...

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are ...

Continuous access to radiation treatment is vital for patients with aggressive cancers, such as those with locally advanced non-small cell lung cancer (NSCLC), who require daily treatments to ...

they've started making advances on this biological chessboard. But doctors still haven't found their checkmate. While people may still be diagnosed with non-small-cell lung cancer, how they're ...

Sugemalimab is already approved for stage 4 NSCLC in Europe and could fill a treatment gap in stage 3 NSCLC. Developed using the OmniRat platform, sugemalimab may reduce immunogenicity and toxicity ...